Breaking News Instant updates and real-time market news.

SLB

Schlumberger

$41.64

0.4 (0.97%)

, BBBY

Bed Bath & Beyond

$14.30

2.04 (16.64%)

07:30
01/11/19
01/11
07:30
01/11/19
07:30

Unusual put flow in option market yesterday

Notable put activity was cited Thursday in Schlumberger (SLB), Bed Bath & Beyond (BBBY), PG&E (PCG), American Eagle (AEO), Royal Caribbean (RCL), Canada Goose (GOOS), Mallinckrodt (MNK), Barclays (BCS), Ligand (LGND), and Clearway Energy (CWEN).

SLB

Schlumberger

$41.64

0.4 (0.97%)

BBBY

Bed Bath & Beyond

$14.30

2.04 (16.64%)

PCG

PG&E

$17.75

-0.07 (-0.39%)

AEO

American Eagle

$19.18

-0.6 (-3.03%)

RCL

Royal Caribbean

$104.93

0.615 (0.59%)

GOOS

Canada Goose

$47.98

-1.21 (-2.46%)

MNK

Mallinckrodt

$19.95

0.67 (3.48%)

BCS

Barclays

$8.11

0.095 (1.19%)

LGND

Ligand

$135.98

-6.03 (-4.25%)

CWEN

Clearway Energy

$16.43

0.36 (2.24%)

  • 14

    Jan

  • 18

    Jan

  • 10

    Feb

  • 03

    Mar

SLB Schlumberger
$41.64

0.4 (0.97%)

12/19/18
12/19/18
DOWNGRADE
Target $44

Neutral
Schlumberger downgraded to Neutral at Credit Suisse
As previously reported, Credit Suisse analyst James Wicklund downgraded Schlumberger to Neutral from Outperform as he updates his sector-wide macro forecasts for a lower expected oil price. In 2019, the analyst sees the overall U.S. rig count declining by about 5%, a 5% decline in completions and a 3% decline in pressure pumping horsepower needed. Wicklund also lowered his price target on the shares to $44 from $65.
12/19/18
FBCO
12/19/18
DOWNGRADE
FBCO
Neutral
Schlumberger downgraded to Neutral from Outperform at Credit Suisse
12/21/18
OTRG
12/21/18
NO CHANGE
OTRG
Pressure Pumping & Completions sector downgraded to Negative at OTR Global
OTR Global downgraded the Pressure Pumping and Completions sector to Negative from Mixed following checks that indicate Major shale E&Ps are lowering 2019 capex plans year-over-year, leading to reduced completion budgets and increasing competition among oilfield service groups.
12/28/18
WELS
12/28/18
NO CHANGE
WELS
Wells sees 'rocky times ahead' for Oil Services and Equipment market
Emerging data points suggest "rocky times ahead" for the North American Oil Services and Equipment market in early 2019, Wells Fargo analyst Judson Bailey tells investors in a research note. As oil prices and macro conditions have weakened to end 2018, a number of recent conversations suggest a "quickly deteriorating" outlook for exploration and production budgets, activity levels and pricing over the first few months of 2019, adds the analyst. He believes the case for "much needed consolidation" across the U.S. oilfield services landscape "has never been greater."
BBBY Bed Bath & Beyond
$14.30

2.04 (16.64%)

11/08/18
SBSH
11/08/18
NO CHANGE
Target $13
SBSH
Sell
Bed Bath & Beyond activist probability low, 'screens well' for LBO, says Citi
Citi analyst Kate McShane reiterated a Sell rating on Bed Bath & Beyond shares, noting that the company has faced and continues to face significant challenges despite having enacted a number of changes in recent years. She views activist involvement or an LBO as a low probability given the number of challenges faced, but added that Bed Bath "has always screened well" as an LBO candidate. In a leveraged buyout scenario, the company could cut the dividend, shut down stores and create a smaller store format as a private company, McShane said.
01/02/19
LOOP
01/02/19
NO CHANGE
Target $12
LOOP
Hold
Loop Capital says Bed Bath Beyond, Amazon price gap widens to historical levels
Loop Capital analyst Anthony Chukumba kept his Hold rating and $12 price target on Bed Bath & Beyond (BBBY), saying his periodic pricing study demonstrated that the gap between the company and Amazon.com (AMZN) has widened back to its "historical level". The analyst sees this as a likely negative for the former, but also notes that that discounting has been a challenge in maintaining its gross margins. Chukumba maintains his forecasts on Bed Bath results ahead of next week's earnings, adding that while its stock trades at a discount to historical average levels, the 6.5-times expected forward earnings multiple is "in line" with other "secularly challenged specialty hardlines retailers."
10/01/18
ARGS
10/01/18
DOWNGRADE
ARGS
Hold
Bed Bath & Beyond downgraded to Hold from Buy at Argus
Argus analyst Christopher Graja downgraded Bed Bath & Beyond to Hold after lowering his earnings estimates to reflect on ongoing gross margin pressure, declines in store traffic and spending on systems and consultants. The disappointing Q2 results amid a very strong retail environment is a concern, Graja tells investors in a research note. The analyst is no longer confident in management's ability to focus on the company's long-term objectives.
10/02/18
LOOP
10/02/18
NO CHANGE
Target $15
LOOP
Hold
Bed Bath & Beyond pricing gap with Amazon narrowed in August, says Loop Capital
Loop Capital analyst Anthony Chukumba kept his Hold rating and $15 price target on Bed Bath & Beyond (BBBY), saying his channel checks indicate a further narrowing of the pricing gap with Amazon (AMZN). The analyst notes the gap in August has shrunk to 13.6% on average vs. 16.9% in July, but also warns that given its position as the "most dynamic retailer" in the U.S. in terms of pricing, Amazon can "quickly and easily lower prices if top-line growth underperforms".
PCG PG&E
$17.75

-0.07 (-0.39%)

12/10/18
WELS
12/10/18
NO CHANGE
Target $47
WELS
Outperform
PG&E price target lowered to $47 from $60 at Wells Fargo
Wells Fargo analyst Neil Kalton lowered his price target for PG&E to $47 from $60 to take into account potential wildfire liabilities. The analyst reiterates an Outperform rating on the shares.
01/02/19
MSCO
01/02/19
NO CHANGE
Target $31
MSCO
Equal Weight
Recent developements for PG&E mixed, not entirely negative, says Morgan Stanley
Morgan Stanley analyst Stephen Byrd noted that PG&E shares underperformed large cap U.S. electric utility peers by about 5% in December. He does not view the numerous recent developments involving PG&E as entirely negative, as the stock move would suggest, but rather sees them as "mixed," with some positives, Byrd tells investors. He sees the CPUC Order Instituting Rulemaking regarding the "stress test" as a positive development and also believes the CPUC Scoping Memo released on December 21 is a development with both positive and negative implications for PG&E, Byrd said. There were also several legal developments in December that were a mix of negative and positive, the analyst added. On the negative side, Byrd lists the CPUC SED report into alleged PG&E falsification of records relating to PG&E's Damage Prevention Program. He maintains an Equal Weight rating on PG&E shares with a $31 price target.
11/19/18
MSCO
11/19/18
NO CHANGE
Target $31
MSCO
Equal Weight
PG&E break-up could be constructive to valuation, but risky, says Morgan Stanley
After California Public Utilities Commission President Michael Picker said the Commission would explore potentially breaking up PG&E, Morgan Stanley analyst Stephen Byrd said he believes a break-up could be constructive to the stock's valuation, but he also sees significant risks to such an approach, identifying the key risk as the regulator, and potentially lawmakers, seeking greater asset coverage for wildfire-related damages beyond the value of the electric utility. He also notes the risk that damages from the Camp Fire could increase from current estimates, given potential liabilities for wrongful death and for air quality damages. Byrd maintains an Equal Weight rating and $31 price target on PG&E shares.
01/04/19
GSCO
01/04/19
UPGRADE
Target $63
GSCO
Buy
Edison International upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs analyst Michael Lapides upgraded Edison International to Buy while lowering his price target for the shares to $63 from $71. The analyst upgrades the shares after their 15% underperformance versus peers since the 2018 wildfires. He also is more positive on longer term potential PG&E (PCG) risk/reward following its 48% underperformance. Both utilities now price in a "very bearish outcome" of the wildfires, says Lapides. He believes that recent commentary from state officials regarding keeping utility balance sheets healthy implies a potential cost sharing of recent wildfire related liabilities.
AEO American Eagle
$19.18

-0.6 (-3.03%)

12/12/18
SBSH
12/12/18
NO CHANGE
Target $27
SBSH
Buy
American Eagle shares 'extremely undervalued' after selloff, says Citi
Citi analyst Paul Lejuez says American Eagle reported another strong quarter in Q3 with total comps up 8% and Aerie comps accelerating sequentially. With the post-earnings selloff in shares implying the core American Eagle business is only being valued at 1.5 times enterprise value to EBITDA despite "still solid" results, the shares are "extremely undervalued at current levels," Lejuez tells investors in a research note. He keeps a Buy rating on American Eagle with a $27 price target.
01/02/19
JEFF
01/02/19
NO CHANGE
JEFF
Buy Gap, sell L Brands are Jefferies' best Consumer ideas for 2019
In the Consumer space, Jefferies analyst Randal Konik says his best ideas for 2019 are buying Gap (GPS) and selling L Brands (LB). The analyst recommends using the late 2018 selloff as an opportunity to get long consumer names for 2019. His other top Buy ideas are American Eagle (AEO), Boot Barn (BOOT), Capri Holdings (CPRI), Five Below (FIVE), Foot Locker (FL), Fox Factory (FOXF), Acushnet Holdings (GOLF), Kohl's (KSS), Manchester United (MANU), Ollie's Bargain Outlet (OLLI), Tiffany (TIF), Urban Outfitters (URBN), Under Armour (UAA) and Yeti (YETI). On L Brands, Konik continues to believe Victoria's Secret "is broken," Pink "is a fad" that's sales will get cut in half, and Bath & Body Works is at a "cyclical peak with daunting compares ahead." On the flip side, the analyst thinks Gap will be one of the top S&P 500 stocks in 2019. He recommends "aggressively" buying the shares at current levels.
12/11/18
LOOP
12/11/18
NO CHANGE
Target $27
LOOP
Buy
American Eagle estimates raised at Loop Capital on accelerating Aerie growth
Loop Capital analyst Laura Champine kept her Buy rating and $27 price target on American Eagle while raising her FY19 EPS view to $1.58 from $1.51 and revenue to $4.40B from $4.19B after the company's Q3 results this evening. The analyst cites the 32% comp growth in the company's Aerie brands, exceeding the American Eagle core brand growth of 5%. She adds that Aerie brand comps have come in at over 20% or more for three years running. Champine further claims that the valuation on American Eagle stock is "inexpensive" at 12-times her expected forward earnings.
12/12/18
UBSW
12/12/18
NO CHANGE
Target $31
UBSW
Buy
UBS sees 'attractive opportunity' to buy American Eagle at current levels
UBS analyst Jay Sole lowered his price target for American Eagle to $31 from $34 but reiterates a Buy rating on the name following yesterday's Q3 results. The company's Aerie brand is on track to deliver its fourth straight year of over 20% comp growth, Sole tells investors in a post-earnings research note. He believes sales can triple over the coming years. With the stock trading "at just" 11.5 tines fiscal 2019 earnings estimates, Sole sees an "attractive opportunity to buy a growth stock at a value multiple."
RCL Royal Caribbean
$104.93

0.615 (0.59%)

01/11/19
DBAB
01/11/19
NO CHANGE
DBAB
Deutsche Bank names Norwegian top 2019 pick in cruise lines
While the cruise lines remain fairly consensus long picks on the sell-side, particularly Royal Caribbean (RCL) and Norwegian Cruise Line (NCLH), the consensus is not always wrong, Deutsche Bank analyst Chris Woronka tells investors in a research note. As the retail sector continues to fight disintermediation from online, gaming has to deal with China macro concerns, and lodging confronts concerns about decelerating corporate room demand, the cruise industry's "wall of worry" appears to be much more manageable to navigate, says the analyst. He sees the industry benefiting from positioning in 2019. Woronka thinks Royal and Norwegian offer the best risk/rewards and names Norwegian his top pick for 2019.
12/21/18
LEHM
12/21/18
NO CHANGE
LEHM
Overweight
Barclays a buyer of Royal Caribbean, Norwegian after yesterday's selloff
Barclays analyst Felicia Hendrix is a buyer of Royal Caribbean (RCL) and Norwegian Cruise Line (NCLH) following yesterday's selloff. Carnival's earnings call yesterday took down all three cruise stocks by "injecting uncertainty regarding Europe into the narrative," Hendrix tells investors in a research note. The analyst acknowledges that there will now be an overhang on the entire group until it becomes clear that this is a Carnival-specific issue. However, it is important to understand that Carnival's strategy in Europe has been operating country-specific brands that source from very specific markets, says Hendrix. The analyst points out that in contrast, Royal Caribbean and Norwegian's brands are globally sourced and marketed, allowing them to fill their ships with customers that will pay the most from anywhere in the world.
11/30/18
STFL
11/30/18
NO CHANGE
Target $157
STFL
Buy
Royal Caribbean shares remain undervalued, says Stifel
After attending an event with Royal Caribbean upper management and members of the travel agent community that was hosted aboard Celebrity Edge, the first new build for the Celebrity brand in over six years, Stifel analyst Steven Wieczynski said he came away with the drivers of his constructive thesis "firmly intact" and he continues to view the shares as undervalued. Echoing what they said during their Q3 call, Royal Caribbean management noted that the company is in a stronger booked position for 2019 than it was in at the same time last year for 2018, noted Wieczynski, who reiterates a Buy rating and $157 price target on the stock.
01/10/19
JPMS
01/10/19
NO CHANGE
JPMS
JPMorgan says stay long Royal Caribbean, Norwegian on 'depressed' valuations
JPMorgan analyst Brandt Montour tells investors to stay long shares of Royal Caribbean (RCL) and Norwegian Cruise Line (NCLH) given the companies' "depressed" valuations. The analyst is positive on Cruise shares in 2019 as he sees "strong/stable" fundamentals. The stocks can outperform from here as operators continue to execute modest organic pricing/net yield growth and low-teens earnings growth, says the analyst. He keeps Overweight ratings on Royal and Norwegian and a Neutral rating on Carnival (CCL).
GOOS Canada Goose
$47.98

-1.21 (-2.46%)

12/17/18
FBCO
12/17/18
NO CHANGE
FBCO
Outperform
Canada Goose stock pullback 'overblown,' says Credit Suisse
Credit Suisse analyst Michael Binetti noted that Canada Goose's stock is down about 22% over the last two weeks amid negative headlines out of China, and tells investors in a research note that he sees no fundamental change to the company's long-term China opportunity, no change to the intrinsic value of the brand, "certainly not enough" to warrant an about $1.8B fall in market cap. The analyst, who has an Outperform rating on the shares, thinks the stock pullback is overblown.
12/10/18
SUSQ
12/10/18
INITIATION
SUSQ
Positive
Canada Goose initiated with a Positive at Susquehanna
Susquehanna analyst Sam Poser started Canada Goose Holdings with a Positive rating and C$98 price target. The analyst views Canada Goose as the "best-in-class, luxury, aspirational cold weather brand steeped in heritage, with significant growth potential." He believes the company is positioned as "THE" luxury winter performance outdoor apparel brand and recommends buying the shares at current levels.
01/03/19
TDSI
01/03/19
UPGRADE
TDSI
Buy
Canada Goose upgraded to Buy from Hold at TD Securities
12/10/18
12/10/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Solid Biosciences (SLDB) initiated with a Neutral at BTIG. 2. Canada Goose (GOOS) initiated with a Positive at Susquehanna. 3. Internap (INAP) initiated with a Buy at Jefferies. 4. Vapotherm (VAPO) initiated with an Outperform at William Blair and a Buy at BTIG, Canaccord, and BofA/Merrill. 5. Gold Fields (GFI) initiated with an Underperform at BMO Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
MNK Mallinckrodt
$19.95

0.67 (3.48%)

12/17/18
MZHO
12/17/18
NO CHANGE
Target $22
MZHO
Neutral
Mallinckrodt price target lowered to $22 from $29 at Mizuho
Mizuho analyst Irina Koffler lowered her price target for Mallinckrodt to $22 while presenting an initial view of how to value the two separate companies. The analyst reduced estimates for Acthar and took a more "conservative stance" on Amitiza's long-term outlook. She also penalized the spin company $2 per share for estimated opioid liability. Koffler ascribes $16 per share to the branded business and $6 to the spin company. She reiterates a Neutral rating on Mallinckrodt.
12/31/18
RILY
12/31/18
NO CHANGE
Target $21
RILY
Neutral
Mallinckrodt price target lowered to $21 from $37 at B. Riley FBR
B. Riley FBR analyst David Buck lowered his price target for Mallinckrodt to $21 after the company earlier this month announced plans to spin off a new company consisting of its specialty generics business and Amitiza to shareholders. The analyst keeps a Neutral rating on the shares.
12/07/18
PIPR
12/07/18
NO CHANGE
Target $39
PIPR
Overweight
Mallinckrodt generics spin-off 'least bad outcome,' says Piper Jaffray
In a research note titled "The Least Bad Outcome for the Generics Business," Piper Jaffray analyst David Amsellem reiterates an Overweight rating on Mallinckrodt with a $39 price target. Given that the generics segment is almost entirely a commodity business, Mallinckrodt not finding a buyer for its active pharmaceutical ingredient and specialty generics businesses is not all that surprising, Amsellem tells investors in a research note. He views yesterday's news of the company announcing a spin-off as the "least bad" outcome. The analyst reiterates an Overweight rating on Mallinckrodt with a $39 price target.
12/07/18
WELS
12/07/18
NO CHANGE
Target $27
WELS
Market Perform
Mallinckrodt investor worries 'worthy of concern,' says Wells Fargo
Wells Fargo analyst David Maris attrubites the 7% selloff yesterday in shares of Mallinckrodt to investors recognizing that the spin-off process could take at least six months and the proceeds previously expected from a sale will now come in the form of levering the spin with debt. Furthering pressing the shares could the realiztioin that the company's opioid and environmental liabilities may not have been fully appreciated, Maris tells investors in a research note partially titled "Questions, But A Reasonable Alternative." The fact that the generics business now has to be consolidated after being reported as a discontinued operation, only to be taken out again when the spin is completed is also challenging for some investors, Maris writes. The analyst, while admitting Mallinckrodt's current cash flow is "very appealing," acknowledges that the re-consolidation and then spin of the generics unit, pending competition of Inomax in 2019, and investor worries about Acthar is "worthy of concern." He maintains a Market Perform rating on Mallinckrodt shares with a $27 price target.
BCS Barclays
$8.11

0.095 (1.19%)

04/16/18
JEFF
04/16/18
UPGRADE
JEFF
Buy
Barclays upgraded to Buy from Hold at Jefferies
Jefferies analyst Joseph Dickerson upgraded Barclays to Buy and raised his price target for the shares to 265p from 205p. Activist Ed Bramson could help unlock significant value in the company's investment bank,Dickerson tells investors in a research note.
06/19/18
BOFA
06/19/18
DOWNGRADE
BOFA
Neutral
Barclays downgraded to Neutral from Buy at BofA/Merrill
BofA/Merrill analyst Andrew Stimpson downgraded Barclays to Neutral from Buy citing share outperformance and lack of significant revenue growth in 2018.
10/01/18
BREN
10/01/18
UPGRADE
BREN
Buy
Barclays upgraded to Buy from Hold at Berenberg
Berenberg analyst Peter Richardson upgraded Barclays to Buy and raised his price target for the shares to 220p from 200p. The analyst views expectations of a 5.5% return on tangible equity as too low and says Barclays has the strongest franchise of any non-U.S. bank. He believes the stock's 20% discount to European peers is unwarranted.
11/09/18
FBCO
11/09/18
DOWNGRADE
FBCO
Neutral
Barclays downgraded to Neutral from Outperform at Credit Suisse
LGND Ligand
$135.98

-6.03 (-4.25%)

11/08/18
HCWC
11/08/18
NO CHANGE
Target $281
HCWC
Buy
Ligand selloff a 'compelling accumulation opportunity,' says H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis says the recent weakness in shares of presents a "compelling accumulation opportunity." The investment case on Ligand is "unchanged" following its Q3 results, Pantginis tells investors in a research note. He views the selloff as "healthy," noting the stock is "letting off of some steam after significant out-performance." The analyst reiterates a Buy rating on Ligand with a $281 price target.
11/13/18
SPHN
11/13/18
NO CHANGE
Target $200
SPHN
Overweight
Ligand recent pullback creates buying opportunity, says Stephens
Stephens analyst Drew Jones lowered his price target on Ligand shares to $200 from $248 following the recent pullback in the shares, but sees a buying opportunity given his expectations for solid royalty trends to remain intact. He thinks macro uncertainty continues to trump fundamentals, but believes company specific worries, such as Promacta competition, Kyprolis "lumpiness" and tough milestone comps for FY19, are "more distraction than material," he tells investors. Jones keeps an Overweight rating on Ligand shares.
10/29/18
10/29/18
UPGRADE
Target $195

Buy
Ligand upgraded to Buy on 'strong' fundamentals at Roth Capital
As previously reported, Roth Capital analyst Scott Henry upgraded Ligand to Buy from Neutral following a 40% decline in the share price. The analyst argues that fundamentals remain strong and lowered 2019 outlook should be more conservative. Further, Henry targets upside to shares even with more conservative numbers. The analyst lowered his price target on the shares to $195 from $250.
11/19/18
HCWC
11/19/18
NO CHANGE
Target $281
HCWC
Buy
Ligand recent selloff 'disconnected from reality,' says H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis says the recent selloff in shares of Ligand Pharmaceuticals is "disconnected from reality." In a research note titled "Stop the Insanity; Physician Survey Refutes Potential Bear Scenario; Reiterate Buy," the analyst tells investors that the recent weakness represents a "unique opportunity, even in these volatile markets." In the end, the focus is on Ligand's growing royalty revenue line and the current pipeline of over 178 partnered assets, Pantginis tells investors in a research note. He reiterates a Buy rating on the shares with a $281 price target.
CWEN Clearway Energy
$16.43

0.36 (2.24%)

01/07/19
GUGG
01/07/19
DOWNGRADE
GUGG
Neutral
Clearway Energy downgraded to Neutral at Guggenheim
As previously reported, Guggenheim downgraded Clearway Energy to Neutral from Buy and cut its price target to $17 from $22. Analyst Shahriar Pourreza expects Clearway shares to work but said it will take time as more comfort is gained with the sponsor, contract quality, and pipeline opportunities.
01/07/19
GUGG
01/07/19
DOWNGRADE
GUGG
Neutral
Clearway Energy downgraded to Neutral from Buy at Guggenheim

TODAY'S FREE FLY STORIES

02:50
01/22/19
01/22
02:50
01/22/19
02:50
General news
FX Update: The Dollar and Yen have traded firmer »

FX Update: The Dollar…

WOLWF

Woolworths Group

$0.00

(0.00%)

18:51
01/21/19
01/21
18:51
01/21/19
18:51
Downgrade
Woolworths Group rating change at Citi »

Woolworths Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLESY

Lendlease Group

$0.00

(0.00%)

18:48
01/21/19
01/21
18:48
01/21/19
18:48
Upgrade
Lendlease Group rating change at Citi »

Lendlease Group upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EFSC

Enterprise Financial

$41.41

0.99 (2.45%)

17:56
01/21/19
01/21
17:56
01/21/19
17:56
Earnings
Enterprise Financial reports Q4 EPS $1.02, consensus 95c »

Reports Q4 core revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

FB

Facebook

$150.01

1.77 (1.19%)

16:36
01/21/19
01/21
16:36
01/21/19
16:36
Periodicals
Facebook planning to add 1,000 jobs in Ireland by year-end, Reuters says »

Facebook will hire an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 30

    Jan

  • 25

    Feb

  • 03

    Mar

FB

Facebook

$150.01

1.77 (1.19%)

16:33
01/21/19
01/21
16:33
01/21/19
16:33
Periodicals
Facebook's WhatsApp limits users to five text forwards, Reuters reports »

Facebook's WhatsApp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 30

    Jan

  • 25

    Feb

  • 03

    Mar

ENB

Enbridge

$36.10

0.425 (1.19%)

16:28
01/21/19
01/21
16:28
01/21/19
16:28
Periodicals
Enbridge gas pipeline explosion creates fireball in Ohio, Reuters says »

An explosion of an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LIN

Linde plc

$160.76

3.48 (2.21%)

16:25
01/21/19
01/21
16:25
01/21/19
16:25
Periodicals
Linde Plc to launch $6B share buyback scheme, Reuters says »

Linde Plc said it would…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

HENKY

Henkel

$0.00

(0.00%)

16:01
01/21/19
01/21
16:01
01/21/19
16:01
Downgrade
Henkel rating change at Goldman Sachs »

Henkel downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAG

Conagra Brands

$21.58

0.34 (1.60%)

14:06
01/21/19
01/21
14:06
01/21/19
14:06
Hot Stocks
Conagra exploring alternatives for Italian-based frozen pasta business »

Conagra Brands announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

13:15
01/21/19
01/21
13:15
01/21/19
13:15
General news
IMF trimmed global growth amid "no-deal" Brexit and trade war concerns »

IMF trimmed global growth…

UQM

UQM Technologies

$1.10

0.05 (4.76%)

13:05
01/21/19
01/21
13:05
01/21/19
13:05
Hot Stocks
UQM Technologies acquired by Danfoss Power Solutions for $1.71 per share »

UQM Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNY

Sanofi

$41.50

-0.54 (-1.28%)

12:37
01/21/19
01/21
12:37
01/21/19
12:37
Hot Stocks
Sanofi granted U.K. marketing authorization for TIV High Dose »

U.K. marketing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 28

    Jan

  • 11

    Mar

  • 22

    Mar

  • 28

    Apr

RTN

Raytheon

$165.11

2.285 (1.40%)

12:33
01/21/19
01/21
12:33
01/21/19
12:33
Hot Stocks
Raytheon awarded $24.36M order for F/A-18 aircraft system repair »

Raytheon said it was a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBCP

Independent Bank

$22.80

-0.11 (-0.48%)

11:26
01/21/19
01/21
11:26
01/21/19
11:26
Hot Stocks
Independent Bank boosts quarterly dividend by 20% to 18c »

Independent Bank…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

11:25
01/21/19
01/21
11:25
01/21/19
11:25
General news
FX Update: The dollar majors have been directionally challenged »

FX Update: The dollar…

EDIT

Editas Medicine

$26.16

-0.01 (-0.04%)

11:25
01/21/19
01/21
11:25
01/21/19
11:25
Hot Stocks
Editas Medicine announces publication of EDIT-101 data in Nature Medicine »

Editas Medicine announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$1,098.25

6.96 (0.64%)

, GOOGL

Alphabet Class A

$1,106.92

7.52 (0.68%)

11:23
01/21/19
01/21
11:23
01/21/19
11:23
Hot Stocks
France's National Data Protection Commission fines Google 50M euros »

France's National…

GOOG

Alphabet

$1,098.25

6.96 (0.64%)

GOOGL

Alphabet Class A

$1,106.92

7.52 (0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 04

    Feb

  • 04

    Feb

  • 25

    Feb

  • 03

    Mar

LAD

Lithia Motors

$87.13

1.57 (1.84%)

10:25
01/21/19
01/21
10:25
01/21/19
10:25
Conference/Events
Lithia Motors to host special shareholder meeting »

Special shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 13

    Feb

  • 14

    Mar

CYDY

CytoDyn

$0.00

(0.00%)

10:25
01/21/19
01/21
10:25
01/21/19
10:25
Conference/Events
CytoDyn participates in lunch meeting with Philadelphia Securities »

Luncheon Meeting with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

ABT

Abbott

$71.43

0.9 (1.28%)

09:50
01/21/19
01/21
09:50
01/21/19
09:50
Hot Stocks
Abbott announces FDA approval of TactiCath Contact Force Ablation Catheter »

Abbott announced FDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 27

    Jan

SFUN

Fang Holdings

$1.88

-0.01 (-0.53%)

09:48
01/21/19
01/21
09:48
01/21/19
09:48
Hot Stocks
Fang announces management changes, proposed China Index spin-off »

Fang Holdings announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TS

Tenaris

$24.32

0.64 (2.70%)

09:45
01/21/19
01/21
09:45
01/21/19
09:45
Hot Stocks
Tenaris closes acquisition of 47.79% of Saudi Steel Pipe shares »

Tenaris S.A. announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAAS

Pan American Silver

$14.17

-0.31 (-2.14%)

09:42
01/21/19
01/21
09:42
01/21/19
09:42
Hot Stocks
Pan American reports 2018 silver production 24.8M ounces »

Pan American Silver Corp.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRWS

Crown Crafts

$5.68

(0.00%)

09:38
01/21/19
01/21
09:38
01/21/19
09:38
Hot Stocks
Crown Crafts announces retirement of NoJo Baby & Kids CEO »

Crown Crafts (CRWS)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.